Methicillin-resistant Staphylococcus aureus (MRSA) acquisition in cystic fibrosis (CF) patients 23 confers a worse clinical outcome with increased rate of declined lung function. Telavancin, an 24 approved lipoglycopeptide used to treat infections due to S. aureus has a dual mode of action 25 causing inhibition of the peptidoglycan synthesis and membrane depolarization. CF-associated 26 MRSA infections remain an important problem with no foreseeable decline in prevalence rates. 27 Although telavancin is currently in clinical use for complicated skin infections and hospital-28 acquired pneumonia, the activity against CF-associated S. aureus infections has not been 29 investigated. In this work, we studied the activity of telavancin against CF S. aureus strains 30 collected from diverse geographical CF centers in the USA. We found that telavancin-MIC90 was 31 0.06 g/ml, 8-fold lower than ceftaroline or daptomycin and 25-fold lower than linezolid and 32 vancomycin. We demonstrate that telavancin at serum-free concentrations has rapid bactericidal 33 activity with a decrease of more than 3 log10 CFU/ml during the first 4 to 6 hours of treatment, 34 performing better in this assay than vancomycin and ceftaroline, including S. aureus resistant to 35 ceftaroline.
INTRODUCTION 44
Methicillin-resistant Staphylococcus aureus (MRSA) is an important infectious human 45 pathogen responsible for diseases ranging from skin and soft tissue infections to life-threatening 46 endocarditis, both in hospitals-(HA) and community-(CA) acquired settings. -lactam resistance in MRSA involves the acquisition of penicillin-binding protein (PBP) 2a, which has low affinity ATCC 25923 TLV-R strains, containing 1.5 x 10 6 CFU/ml, as previously described (21) . Inoculum 111 was administered directly to the larval hemocoel through the last left pro-leg as previously 112 described (17, 22) . Every trial included a group of 10 untreated larvae as uninfected control group 113 and 10 larvae injected with PBS as a method control. Experiments were performed in at least three 114 independent trials. Injected insects were monitored over seven days at 37°C. By the day seven, 115 pupa formation was recorded in survived larvae. infections. Among all strains, TLV -MIC 90 was 0.06 mg/L, i.e. 8-fold lower than DAP and CPT, 141 and 25-fold lower than LZD and VAN. In the strains with reduced CPT susceptibility, the TLV 142 MIC 90 was 0.06 g/ml for both CPT-IR TMH-5006 and CPT-HR TMH-5007 strains, showing the 143 absence of cross-resistance between both antibiotics (Table 1) . Of note, although DAP showed in- 
149
Of note, we found in AMT-0067-21 strain the presence of internal colonies in TLV E-test for 150 strain and displaying (MIC: 0.19 g/ml; homogeneous up to 0.047g/ml) and a broth 151 microdilution MIC at 0.25 µg/L. Interestingly, the tested MRSA and MSSA strains were not 152 associated to VISA or DAP non susceptible phenotype. These data altogether provide evidences 153 that TLV retain potency against S. aureus CF strains.
CPT. The assay was performed in Muller-Hinton broth supplemented with 0.002% polysorbate -80 157 for TLV and calcium 50 g/ml for DAP, against a representative number of CF-strains including a 158 high CPT-R (TMH-5007) strain. (18) (19) (20) . TLV showed activity against all the tested strains 
164
Together these data support the potential therapeutic application of TLV for the treatment of S. 165 aureus CF infections.
166
In-vitro selection of TLV resistant mutants. To determine the fate of mutation selection that 167 can be projected by the potential prolonged use of TLV in CF patients we investigated the ease of 168 in-vitro selection from three clinical CF representative strains: AMT 0114-8, WIS 664 and 169 TMH5007 (CPT-HR) strain. S. aureus ATCC 25923 was included as a non-CF strain control.
170
These strains were serial passaged at sub-inhibitory concentrations of TLV starting at 0.03 g/ml 171 and escalating up to 3g during 40 days. After 15 days, the strains showed an increase in TLV vertebrates, and numerous enzymatic cascades akin to complement fixation and blood coagulation 203 occur in the hemolymph, resulting in hemolymph clotting and melanin production as key defense 204 mechanisms against invading microbes. These tissue types are similar to those encountered by S. 205 aureus during invasive infections in humans (22).
206
Groups of larvae (10/group) were inoculated with a bacterial suspension containing parent strains 207 AMT 0114-48 , WIS 664 and a control ATCC 25913 and their corresponding TLV in-vitro 208 derivative mutants AMT 0114-48 TLV-R, WIS 664-TLV-R and ATCC 25913-TLV-R (10 6 209 bacteria/worm) as previously described (22). An uninfected control group received PBS treatment 210 to control for multiple injections. Worms were daily monitored and recorded for any deaths during 211 10 days. Worms injected with PBS showed 100/90% survival at day 8 ( Figure 2 ), but groups of 212 parent strains (e.g. AMT 0114-8) displayed low survival rates (≤50-0%, day 6; Figure 2 ). By 213 contrast, groups of worms infected with TLV-R strains (e.g. AMT 0114-48-TLV-R) resulted in 214 survival rates of 90% at day 6 followed by 60% survival at day 8. Similar trend was observed with 215 the ATCC 25923 strain although the survival rate was higher (40%) than parent S. aureus CF 216 strain (0-20%) while TLV-R strains were comparable in survival. These results may suggest that 217 TLV-R is associated with changes in virulence fitness.
218

DISCUSSION
219
Infection with S. aureus remains an important concern for CF patients with consistently high 220 prevalence in this population. Chronic MRSA infections associated with worse outcomes and 221 treatment eradication is a continual clinical challenge. For MRSA pneumonia the most widely 222 recommended antibiotics are vancomycin and linezolid, with TLV also approved for this infection was performed retrospectively to assess the activity of TLV in S. aureus isolated from three resistance may be infrequent, modest increases in MICs may be seen in some isolates as the one 249 described here (TLV MIC 0.19 g/ml) and in some strains with VAN and DAP decreased 250 susceptibility. In this context, it was advantageous to gain an understanding of the ease of TLV 251 resistance when CF strains are extensively exposed to sub-therapeutic TLV in-vitro exposure.
252
After 15 days, the strains showed an increase in TLV MIC from 0.06 g/ml up to 0.25 -1 g/ml, 253 which is above the susceptible breakpoint of 0.12 µg/mL for S. aureus, followed by a 254 progressive increase up to 3 µg/ml after 40 days of exposure. These observations may imply that 255 resistance should be monitored in patient receiving repeated and/or prolonged treatment by TLV.
256
In a previous study performed by (25) one stable mutant was obtained after 43 days in multistep 257 resistance selection studies from one of the ten MRSA strains, correlating with low mutation 258 frequency. Interestingly in our study, we were able to demonstrate that the TLV resistance 259 selection was independent of the CF -S. aureus background strains considering the fact that we 260 were able to obtain a TLV-R mutant from an ATCC 25923. We determined next the main 261 genetic changes associated to TLV-R with full genome sequencing of a representative number of 262 in-vitro obtained TLV-R strains along with the in-vivo derived CF-TLV-R that showed a modest 263 increase of MIC (0.19g/ml). We found that TLV-R harbored common mutations in genes 264 associated to cell wall (e.g. murE, tagB) and cell wall surface (spa, clfB, sdrE) genes. In the TLV 265 obtained in previous studies by Song Y et al (26)most of the differential expressed genes were 266 also associated to changes in cell envelope. These findings suggest that although TLV is an agent 267 with dual mechanism (cell membrane/cell wall) the compensatory preferential mutational 268 mechanism seems to be in higher degree linked to cell wall (CW). These cell wall mutations 269 may also function in a dual manner to reduce TLVs cell membrane mechanism potency. This is 270 evidenced by prior studies correlating mutations and reduced VAN susceptibility as a result of VAN treatment (VISA strains) with collateral reduced DAP activity. Similarly, in our study the 272 derived TLV-R mutants showed cross-resistance with reduced susceptibility to both VAN (MIC 273 3-6 µg/ml) and DAP (MIC 6-8 µg/ml).
274
Another set of genes in were we found non-synonymous SNPs were related to virulence (e.g. sdrE, 275 spa, clfB). These changes appeared to suggest that TLV-R affects S. aureus virulence fitness as Parent strains ATCC 25923 and AMT 0114-18 are indicated in red line , mutants ATCC 25923 -TLVR and AMT0114-48 TLVR ,indicated in green , infected at doses 10 6 bacteria/worm and PBPS uninfected worms ( blue) . Survival was monitored during 10 days. Figure 2 
